Table 3.
Initial and final values on primary outcomes and covariates by exercise group from baseline to 12 months
| Characteristic | POWIR (n = 36)
|
FLEX (n = 31)
|
F(df)* | P value* | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline Mean (SD) | 12 Months Mean (SD) | % Change | Baseline Mean (SD) | 12 Months Mean (SD) | % Change | |||
| Body weight | 75.6 (15.5) | 76.5 (15.6) | 1.19 | 74.0 (12.3) | 74.2 (12.3) | 0.27 | 0.57 (2,106) | 0.55 |
| Bone-free lean mass (kg) | 43.4 (6.5) | 44.0 (6.7) | 1.38 | 44.7 (5.8) | 45.2 (6.0) | 1.12 | 0.09 (2,122) | 0.91 |
| Fat mass (kg) | 30.4 (9.4) | 30.9 (9.7) | 1.64 | 29.0 (8.2) | 29.0 (8.1) | 0.00 | 0.65 (2,122) | 0.50 |
| % Body fat | 40.5 (5.7) | 40.5 (6.2) | 0.00 | 38.7 (5.6) | 38.5 (5.8) | −0.52 | 0.66 (2,122) | 0.51 |
| Spine (L1–L4) BMD (g/cm2) | 0.983 (0.146) | 0.987 (0.146) | 0.41 | 0.971 (0.120) | 0.949 (0.108) | −2.27 | 7.05 (2,122) | < 0.01 |
| Total hip BMD (g/cm2) | 0.863 (0.101) | 0.860 (0.105) | −0.35 | 0.848 (0.099) | 0.841 (0.096) | −0.83 | 2.10 (2,122) | 0.13 |
| Greater trochanter BMD (g/cm2) | 0.657 (0.088) | 0.654 (0.087) | −0.46 | 0.642 (0.091) | 0.641 (0.089) | −0.156 | 1.94 (2,122) | 0.15 |
| Femoral neck BMD (g/cm2) | 0.731 (0.100) | 0.721 (0.101) | −1.37 | 0.728 (0.091) | 0.713 (0.082) | −2.06 | 1.34 (2,122) | 0.27 |
| Osteocalcin (ng/ml)a | 12.6 (4.4) | 12.8 (3.8) | 1.59 | 11.3 (4.1) | 14.3 (5.0) | 26.5 | 4.79 (2,108) | 0.01 |
| Deoxypyrodinoline (nmol/mmolCr) | 21.4 (9.8) | 13.1 (4.2) | −38.8 | 17.1 (5.6) | 12.2 (3.1) | −28.7 | 1.57 (2,110) | 0.22 |
| Energy expenditure (kcal/d)b | 434.3 (300.1) | 430.8 (281.4) | −0.81 | 458.9 (346.4) | 461.7 (346.4) | 0.61 | 0.07 (2,122) | 0.94 |
| Energy intake (kcal/d) | 1331.2 (449.5) | 1347.6 (441.2) | 1.23 | 1549.6 (553.4) | 1501.6 (557.0) | −3.10 | 1.23 (2,98) | 0.30 |
| Calcium intake (mg/day)c | 694.6 (333.9) | 751.0 (356.8) | 8.12 | 797.1 (294.1) | 723.6 (297.9) | −9.22 | 1.85 (2,98) | 0.16 |
Data presented as unadjusted mean (SD) for participants with complete data sets for both time points
F and P value (using Huynh–Feldt adjustment for sphericity) from RM-ANCOVA for the time by group interaction that included baseline, 6 and 12 month time points and controlled for the following: age, time since diagnosis, current adjuvant hormone therapy use. P values are observed and not corrected for multiple testing
Sample size for biomarkers was N = 33 for POWIR and N = 28 for FLEX
Energy expenditure calculated from CHAMPS physical activity survey and includes energy expended in activities ranging from low to vigorous intensity per week
Calcium intake includes calcium obtained both from dietary sources and from dietary supplements